Raymond James Trust N.A. Sells 3,513 Shares of Henry Schein, Inc. (NASDAQ:HSIC)

Raymond James Trust N.A. decreased its position in Henry Schein, Inc. (NASDAQ:HSIC) by 53.8% during the 3rd quarter, Holdings Channel reports. The firm owned 3,015 shares of the company’s stock after selling 3,513 shares during the period. Raymond James Trust N.A.’s holdings in Henry Schein were worth $220,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Charles Schwab Investment Management Inc. lifted its stake in Henry Schein by 0.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,175,061 shares of the company’s stock worth $85,662,000 after acquiring an additional 6,184 shares during the period. Thompson Siegel & Walmsley LLC lifted its position in shares of Henry Schein by 37.7% in the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 1,003,041 shares of the company’s stock worth $73,122,000 after purchasing an additional 274,756 shares during the period. Cypress Capital Group bought a new stake in shares of Henry Schein during the 3rd quarter valued at about $224,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its position in shares of Henry Schein by 5.9% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 122,721 shares of the company’s stock valued at $8,946,000 after buying an additional 6,826 shares during the period. Finally, Nuance Investments LLC raised its stake in Henry Schein by 22.3% in the third quarter. Nuance Investments LLC now owns 2,278,081 shares of the company’s stock worth $166,072,000 after buying an additional 414,748 shares in the last quarter. 96.62% of the stock is owned by hedge funds and other institutional investors.

Henry Schein Trading Up 0.5 %

NASDAQ:HSIC opened at $77.66 on Friday. The stock has a market cap of $9.68 billion, a price-to-earnings ratio of 31.96, a PEG ratio of 2.20 and a beta of 0.87. The company has a quick ratio of 0.82, a current ratio of 1.42 and a debt-to-equity ratio of 0.46. The company’s 50 day moving average price is $71.26 and its 200-day moving average price is $69.84. Henry Schein, Inc. has a 52 week low of $63.67 and a 52 week high of $82.63.

Henry Schein (NASDAQ:HSIC) last posted its earnings results on Tuesday, November 5th. The company reported $1.22 EPS for the quarter, topping analysts’ consensus estimates of $1.17 by $0.05. The business had revenue of $3.17 billion during the quarter, compared to analyst estimates of $3.24 billion. Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The company’s quarterly revenue was up .4% compared to the same quarter last year. During the same quarter last year, the company earned $1.32 EPS. On average, equities research analysts forecast that Henry Schein, Inc. will post 4.78 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

HSIC has been the topic of a number of research analyst reports. UBS Group reduced their target price on Henry Schein from $75.00 to $72.00 and set a “neutral” rating on the stock in a report on Wednesday, August 7th. Barrington Research reiterated an “outperform” rating and issued a $82.00 price objective on shares of Henry Schein in a report on Wednesday, November 6th. JPMorgan Chase & Co. dropped their target price on shares of Henry Schein from $88.00 to $80.00 and set an “overweight” rating on the stock in a report on Monday, August 12th. Evercore ISI increased their price target on shares of Henry Schein from $70.00 to $74.00 and gave the stock an “in-line” rating in a research note on Tuesday, October 8th. Finally, Robert W. Baird dropped their price objective on shares of Henry Schein from $92.00 to $82.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 7th. Six equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Henry Schein presently has an average rating of “Moderate Buy” and a consensus target price of $79.38.

Insiders Place Their Bets

In other Henry Schein news, SVP Lorelei Mcglynn sold 21,035 shares of the business’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $69.30, for a total transaction of $1,457,725.50. Following the completion of the sale, the senior vice president now directly owns 71,833 shares in the company, valued at approximately $4,978,026.90. The trade was a 22.65 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Michael S. Ettinger sold 12,240 shares of the firm’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $75.00, for a total value of $918,000.00. Following the completion of the transaction, the chief operating officer now owns 87,706 shares in the company, valued at approximately $6,577,950. This trade represents a 12.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.14% of the stock is owned by insiders.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.